Overview

A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Celldex Therapeutics